Oral Thin Film Drugs Market Research Report – Forecast to 2023 segmented by Product (Fast Dissolving Buccal Film, Sublingual), by Disease Indication (Opioid Dependence, Nausea & Vomiting, Schizophrenia, Migraine), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Drug Stores), and Region, Confirms MRFR
GET FREE SAMPLE COPY FOR ADVANCE FORECAST @
https://www.marketresearchfuture.com/sample_request/6547
Leading Manufacturers
Players leading the global oral thin film drugs market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), CURE Pharmaceutical (US), Novartis AG (Switzerland), LTS Lohmann Therapie-Systeme AG (Germany), GlaxoSmithKline Plc (UK), and Indivior Plc (US), among others.
Oral Thin Film Drugs Market Overview
The global oral thin film drugs market is proliferating, mainly due to the increasing popularity of these wafers for their effective administering of medicines. According to a leading research firm -Market Research Future (MRFR), the global oral thin film drugs market is estimated to grow significantly by 2023, registering a CAGR of 10.50% throughout the forecast period (2018-2023).
Orally Dissolvable Thin Film (ODF) or sublingual/ wafers is a drug delivery mechanism, developed with paper-thin polymer films that carry pharmaceutical agents. Besides, ease in administering, ODF drugs deliver multiple benefits, such as they do not require water or swallowing, and they dissolve quickly in the oral cavity with the active ingredient rapidly absorbed & diffused directly in the bloodstream.
The absorbed active ingredient can bypass the liver’s first-pass effect, improving therapeutic outcomes & efficacy through enhanced bioavailability. ODF drugs facilitate excellent patient compliance and are suitable for a wide range of patients, including geriatric & pediatric patients who experience difficulty swallowing. Resultantly, the ODF drugs are gaining immense popularity worldwide.
Table of Content:
4 Market Dynamics
4.1 Overview
4.2 Drivers
4.2.1 Growing Demand For Oral Thin Film Drugs
4.2.2 Increasing Geriatric Population
4.3 Restraints
4.3.1 Drugs Which Irritate The Mucosa Or Causes Ulcers Cannot Be Administrated By The Oral Route
4.3.2 Drug With A Small Dosage Form Can Only Be Administrated
4.3.3 Drugs Which Are Unstable At Buccal PH Cannot Be Administered
4.3.4 Stringent Regulations
4.4 Opportunities
4.4.1 Introduction Of Oral Thin Film Drugs In Developing Regions
4.4.2 Increasing Investments In Research & Innovations
5 Market Factor Analysis
5.1 Porter’s Five Forces Model 2
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.2.1 Research & Development
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
5.3 Investment Opportunities
5.4 Macroeconomic Indicators
Continued….
Global Oral Thin Film Drugs Market Segmentation
The market is segmented into four dynamics to widen the scope of understanding,
By Product: Fast Dissolving Buccal Film and Sublingual.
By Disease Indication: Nausea & Vomiting, Opioid Dependence, Schizophrenia, Migraine, and others.
Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Drug Stores, and others.
By Regions: Europe, North America, APAC, and the Rest-of-the-World (RoW).
Oral Thin Film Drugs Market – Competitive Landscape
Highly competitive, the oral thin film drugs market appears to be fragmented due to the presence of many well-established players. Players incorporate strategic approaches such as mergers & acquisitions, collaborations, expansion, and technology launch to gain a substantial share in this market. They also substantially invest in R&D and clinical trials to accelerate product development & innovations and to cut down production costs.
Browse Complete 100 Pages Premium Research Report @ https://www.marketresearchfuture.com/reports/oral-thin-film-drugs-market-6547
Industry/Innovation/ Related News:
October 08, 2019 —- Aurora Cannabis Inc. (Canada), a licensed cannabis producer and CTT Pharmaceutical Holdings, Inc., announced the successful commercialization of CTT’s cannabinoid-infused orally dissolvable thin film (ODF)/ sublingual/ wafers.
The new cannabis product line is a first of its kind medicine that been launched under the brand name “Dissolve Strips™” in the Canadian medical cannabis market. The launch of Dissolve Strips™ is a significant milestone for Aurora that signifies the transition of CTT from a technology development phase to a revenue-generating phase. Aurora also confirms that the next stage in its development is to launch a broader portfolio of unique products on a global scale. These companies have been working towards and look forward to reporting on their progress in the coming quarters.
Related News
Medicated Personal Care Products Market – Global Forecast 2027
Bariatric Surgery Devices Market – Global Forecast 2023
About Market Research Future:
MRFR team has supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country-level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with the technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312